The 10th Annual Immuno-Oncology Summit was held in Boston during October 12-14, 2022. Creative Biolabs, as an exhibitor, successfully showcased at the 10th Annual Immuno-Oncology Summit at booth #9 and has attractedRead More…
Bispecific antibody (bsAb) refers to a molecule that can bind to two different antigens or to two different epitopes of the same antigen. The concept of bsAbs was first proposed by NisonoffRead More…
Recently, Amgen announced the long-term efficacy of the company’s bispecific antibody Blincyto (blinatumomab) in the treatment of patients with acute lymphoblastic leukemia (ALL) at the European Hematology Association (EHA) conference. The medianRead More…
TG Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for patients with B-cell-mediated diseases. Recently, the company announced the launch of TG-1801 ‘s first human Phase I study, a new,Read More…
French pharmaceutical giant Sanofi recently announced that the US Food and Drug Administration (FDA) has approved the single-domain antibody (sdAb) drug Cablivi (caplacizumab) combined with plasma exchange and immunosuppressive therapy, for theRead More…
Immunotherapy was positioned as an emerging and even promising treatment for cancer. Today’s new immunotherapeutic agents for different tumor types, whether used alone or in combination, are increasingly becoming one of theRead More…
Amgen, the United States biotechnology giant, recently announced that the Ministry of Health, Labor and Welfare (MHLW) has approved bispecific T cell engager immunotherapy Blincyto® (blinatumomab) for the treatment of relapsed orRead More…